Ordinary Shares, $0.001 par value
- Symbol
- STE
- Exchange
- NYSE
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 2.05, 9.01 · 8-K
STERIS plc
STENYSEEQUITYCurrent
Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, STERIS plc (the “Company” or "STERIS") issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1.…
Press release in this filing
STERIS Announces Financial Results for Fiscal 2027 Second Quarter →Company context
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. For more information, visit www.steris.com.
Current securities
Recent company filings
- 10-Q filingNov 5, 2026
- Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementNov 4, 2026
- Entry into a Material Definitive AgreementOct 13, 2026
- 4 filingOct 5, 2026
- 144 filingAug 18, 2026
Registered securities in this filing
STERIS plc · 8-K · Filed 2026-11-04
2.700% Senior Notes due 2031
- Symbol
- STE/31
- Exchange
- NYSE
- Classification
- DEBT
3.750% Senior Notes due 2051
- Symbol
- STE/51
- Exchange
- NYSE
- Classification
- DEBT
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 4, 2026, STERIS plc (the “Company” or "STERIS") issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 2.02 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.
Filed exhibits (1)
Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 Second Quarter • Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8% • Fiscal 2027 second quarter as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94 • Outlook updated to reflect solid underlying performance and the benefit of tariff refunds DUBLIN, IRELAND - (November 4, 2026) - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Total revenue for the second quarter of fiscal 2027 increased 9% to $1.6 billion compared with $1.5 billion in the second quarter of fiscal 2026. Constant currency organic revenue growth was 8% in the second quarter. “We are pleased with our second quarter performance,” said Dan Carestio, President and CEO of STERIS. “Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year. Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date. Fiscal 2027 is shaping u…
Open exhibit ↗